Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
san francisco blog main
4
×
national top stories
new york blog main
rna interference
san francisco top stories
alnylam pharmaceuticals
barry greene
biotech
boehringer ingelheim
clinical trials
dan ollendorf
deals
eli lilly
new york top stories
sanofi
akcea therapeutics
alexion pharmaceuticals
alnylam pharmaceutials
amy schulman
andreas klein
anna greka
arrowhead pharmaceuticals
biontech
boston university
car-t
caron jacobson
cigall kadoch
craig mello
curevac
dicerna pharmaceuticals
drugs
events
fda
foghorn therapeutics
gene therapy
What
rna
4
×
medicines
ago
companies
deal
interference
time
abandoning
alnylam
approve
aren’t
awaits
baggage
bets
bio
biological
cancer
car
comes
crossed
cut
cuts
cutting
date
decades
decision
development
dicerna
discovered
edge
effective
enticed
evidence
experiments
fda
fingers
free
friday
gene
gets
Language
Current search:
boston
×
rna
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
